Clinical Trials Logo

Clinical Trial Summary

The first-line treatment strategy of moderate to severe UC was a important question at issue. The biological agents had potentiality to alter the disease course of UC. The AGA clinical guidelines had conditional recommend that IFX and other biological agene migtht be first-line therapy for high-risk UC patints but only had low grade evidence.We launched this multicenter prospective cohort trial to compare the efficacy and safety of infliximab (IFX) and corticosteroids(CS) when they was used as first-line therapy in UC patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04879966
Study type Observational
Source Sixth Affiliated Hospital, Sun Yat-sen University
Contact
Status Recruiting
Phase
Start date May 17, 2021
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Withdrawn NCT03627052 - A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis Phase 2
Recruiting NCT05486104 - Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis Phase 2
Terminated NCT02092389 - Fecal Calprotectin Levels, QoL and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo N/A
Completed NCT04700449 - A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC) Phase 2
Completed NCT04090411 - A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis Phase 2